The abstract is read at the publisher; the summary is JClub's.
Temporary interruption of adjuvant endocrine therapy for pregnancy in HR-positive early breast cancer patients (≤42 years) is linked to 5-year BCFI event incidence of 12.3% in POSITIVE.
- Why it matters: The trial addresses whether pausing endocrine therapy to attempt pregnancy is feasible and safe beyond early follow-up, especially given the risk of late recurrence in this population.
- What they did: POSITIVE enrolled 518 eligible women (stage I–III) and used bootstrap-matching to compare 5-year breast cancer-free interval and distant recurrence-free interval event rates with SOFT/TEXT external controls.
- The result: With median follow-up of 71 months (POSITIVE) and 80 months (SOFT/TEXT), 5-year DRFI events were 6.2% vs 8.3% (difference −2.1%, 95% CI −4.5% to 0.4%), implying no increased BC event risk with longer follow-up.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.
- 1 cited this week
- Open access